Stem Cell Educator Therapy for Health & Longevity

Created on 11/20/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Stem Cell Educator therapy, an experimental procedure, passes a person's own white blood cells over donor cord blood stem cells and returns them, aiming to retrain an immune system that attacks the body's own tissues. One small type 1 diabetes study suggests better blood glucose control; other results lack comparison groups, and healthy ageing is untested. Short-term risks appear modest; nearly all evidence comes from the inventor. (Full Review)

Protocol

Closed-loop single session (inventor's protocol)
6–7 hours of apheresis
At 35 mL/min; cells co-cultured 2–3 hours in the device, then returned through a hand vein
Cell dose
About 10 liters of blood processed
Roughly 10 billion of the person's white blood cells exposed to about 10 million donor cord blood stem cells (1:20 to 1:50)
Single versus split sessions
One session, or a second at 3 months
Chinese trials used one session; the Spanish trial added a second to reach cells sheltered in lymph nodes
Time to effect
Blood glucose control (HbA1c)
4–12 weeks
HbA1c fall reported at 12 weeks in both type 1 and type 2 diabetes trials
Hair regrowth in alopecia areata
From 4 weeks
Complete regrowth in some at 12 and 16 weeks, sustained at 2 years
Remission of Crohn's disease
5 weeks
Biopsies without inflammation at 5 weeks and 6 months in a single case

Benefits

Contraindications
  • Hemodynamic instability or severe heart disease (e.g., New York Heart Association class III–IV heart failure)
  • Multiple myeloma or known hypocalcemia
  • Pregnancy
  • Active infection
  • People awaiting organ or stem cell transplantation
Key Interactions
  • Insulin: unchanged doses risk hypoglycemia
  • Metformin: continued full dosing adds glucose lowering
  • Oral calcium, vitamin D3 and magnesium (supplements): prophylactic intake eliminated citrate reactions during apheresis
Theoretical (inferred from mechanism)
  • ACE inhibitors (lisinopril): allergic-like reactions
  • Sulfonylureas and other oral glucose-lowering drugs (glipizide, repaglinide): hypoglycemia
  • Immunosuppressants and immune biologics (prednisone, teplizumab): could blunt the intended immune "education" or add infection risk
  • Anticoagulants and antiplatelet drugs (warfarin, clopidogrel): bruising or bleeding
  • Over-the-counter NSAIDs (ibuprofen): more bleeding at puncture sites
  • Blood-pressure-lowering drugs (amlodipine): dizziness or fainting
  • Antiplatelet supplements (fish oil): bleeding at access sites
  • Immune-modulating supplements (high-dose vitamin D): confounded immune-marker monitoring
  • Vaccination: possibly weaker vaccine responses
  • Blood donation or other apheresis: anemia or low platelets

Risk & Side Effects

  • High: [risks_high]
  • Medium: [risks_medium]
  • Low: Apheresis discomfort and citrate reactions; hypoglycemia after treatment; serious adverse events
  • Speculative: Infection from processing outside the body; sensitization to donor tissue types; weakened immune defense

Monitoring

Marker Target Why
Fasting C-peptide 0.3–3.3 ng/mL Own insulin output
Stimulated C-peptide Not specified in the ER Own insulin output
HbA1c Below 7% 3-month glucose average
CGM time in range (70–180 mg/dL) Above 70% Daily glucose control
CGM time below 70 mg/dL Below 4% Hypoglycemia as insulin needs fall
Daily insulin dose Not specified in the ER Changing insulin needs
Regulatory T cells (CD4⁺CD25⁺FOXP3⁺) No established target; track change from own baseline Proposed immune mechanism
Platelet count 150–400 × 10⁹/L Apheresis blood-cell loss
HLA antibody screen (transplant candidates) Not specified in the ER Donor sensitization

Cadence: Baseline panel before the session; then at 4, 12, 24 and 40 weeks after it, then every 6–12 months. Continuous glucose monitoring throughout the first 12 weeks; platelets before and 24 hours after the session.

Qualitative Assessment

  • Frequency and severity of hypoglycemia episodes and hypoglycemia awareness
  • Energy, fatigue and mental clarity, especially after long COVID
  • Hair regrowth on standardized photographs in alopecia areata
  • Bowel symptoms in inflammatory bowel disease
  • Frequency of infections in the year after treatment